The mean duration of hospitalization in the MYDICA group high dose during the 12-month period 0.


The mean duration of hospitalization in the MYDICA group high dose during the 12-month period 0.4 days 0.4 days compared to 4.5 days per patient in the placebo group. This finding is particularly noteworthy because heart failure is the most common cause of hospitalization in Americans 65 years of age and older.

The disease that is untreated by a less severe condition to a more serious one progress.. About the CUPID trial – announced the results of Phase 2 CUPID trial met its primary safety and efficacy endpoints at 6 months for high dose MYDICA compared to placebo. Additionally, 12 months after receiving a single infusion of MYDICA, patients with the highest dose , compared with placebo, 88 % risk reduction of major cardiovascular events such as death, need for left ventricular assist device or cardiac transplant, episodes of worsening heart failure and number of heart failure – related hospitalizations.

Determining whether a disease is a matter of judgment a matter of judgment, but in general from getting day, orr the drug acting influence of factors such as survival, day-to – day, or have the probability based on that.Building on this heritage, Amgen advanced Aranesp, a unique erythropoiesis stimulatory protein, this two more sialic acids -containing carbohydrate chains of than that Epoetin alfa molecules includes and stays to the circulation Greater a epoetin alfa, since it has a longer half-life. By his longer half-life, administration administered less frequent as Epoetin alfa patients with chronic kidney disease . In July 2002 permitted for multiple indications of different Dosage the United States and in Europe. Aranesp been of September 2001 in September 2001 and two weekly dosage to treat anemia associated with chronic renal, and known as CKD Tweaking and patient no at dialysis.

Our products against products that have lower prices, founder of repayment, superior performance, are competing, easier to administer, or that else compete with our products. Moreover while we routinely obtained patents for our products and technology, of protection of our patents and patents available been challenged, be canceled or circumvented out from our competitors, and it can gain no guarantee our ability to or maintaining patent protection for our his product article groups or candidates.